FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794897677> ?p ?o ?g. }

• W2794897677 abstract "Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination therapy of bevacizumab, cisplatin, and docetaxel in chemotherapy-naive Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC).Eligible patients were chemotherapy-naive and had advanced/recurrent non-squamous NSCLC. The patients received 4 cycles of docetaxel (60 mg/m2), cisplatin (80 mg/m2), and bevacizumab (15 mg/kg) once every 3 weeks, followed by bevacizumab as maintenance therapy, every 3 weeks until disease progression or attainment of unacceptable toxicity level. The primary endpoint was objective response rate (ORR). The numbers of circulating endothelial cells (CEC) were also estimated on days 1 and 8 of the first cycle for the exploratory analysis of efficacy prediction.A total of 47 patients were enrolled from October 2010 to April 2012. Bevacizumab as maintenance therapy was administered to 41 patients (87.2%), and the median number of total treatment cycles was 9 (range: 1-36). ORR, median progression-free survival (PFS), and median overall survival of the patients were 74.5%, 9.0 months, and 27.5 months, respectively. The most common grade 3/4 adverse event was neutropenia (95.7%), followed by leukopenia (59.6%) and hypertension (46.8%). PFS was longer in patients with ≥10 count increase in CECs than that in patients with < 10 count increase in CECs (respective median PFS of 11.0 months versus 6.90 months) although the difference was not statistically significant (p = 0.074).A combination therapy of bevacizumab, cisplatin, and docetaxel, followed by bevacizumab as maintenance was highly effective in patients with non-squamous NSCLC despite the high incidence of grade 3/4 neutropenia. The increase in CEC count between days 1 and 8 may predict the efficacy of our bevacizumab-contained treatment regimen.UMIN Clinical Trial Registry; UMIN000004368 . Registered date; October 11, 2010 (Retrospectively registered)." @default.
• W2794897677 created "2018-04-06" @default.
• W2794897677 creator A5003648443 @default.
• W2794897677 creator A5004024254 @default.
• W2794897677 creator A5004383942 @default.
• W2794897677 creator A5021722390 @default.
• W2794897677 creator A5022026164 @default.
• W2794897677 creator A5030688973 @default.
• W2794897677 creator A5036440015 @default.
• W2794897677 creator A5041846056 @default.
• W2794897677 creator A5047998541 @default.
• W2794897677 creator A5052453881 @default.
• W2794897677 creator A5053859585 @default.
• W2794897677 creator A5054884728 @default.
• W2794897677 creator A5057044706 @default.
• W2794897677 creator A5065387771 @default.
• W2794897677 creator A5066841617 @default.
• W2794897677 creator A5073524299 @default.
• W2794897677 creator A5077430155 @default.
• W2794897677 creator A5084744867 @default.
• W2794897677 creator A5087535894 @default.
• W2794897677 creator A5091073688 @default.
• W2794897677 date "2018-03-02" @default.
• W2794897677 modified "2023-10-12" @default.
• W2794897677 title "Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016" @default.
• W2794897677 cites W1758017998 @default.
• W2794897677 cites W1823686527 @default.
• W2794897677 cites W1914960099 @default.
• W2794897677 cites W1998276910 @default.
• W2794897677 cites W2009337734 @default.
• W2794897677 cites W2014687655 @default.
• W2794897677 cites W2037139573 @default.
• W2794897677 cites W2048776837 @default.
• W2794897677 cites W2048829586 @default.
• W2794897677 cites W2056647735 @default.
• W2794897677 cites W2058813771 @default.
• W2794897677 cites W2060251426 @default.
• W2794897677 cites W2080821717 @default.
• W2794897677 cites W2097026987 @default.
• W2794897677 cites W2102628344 @default.
• W2794897677 cites W2103158778 @default.
• W2794897677 cites W2109823414 @default.
• W2794897677 cites W2115078104 @default.
• W2794897677 cites W2122798232 @default.
• W2794897677 cites W2123230605 @default.
• W2794897677 cites W2130334661 @default.
• W2794897677 cites W2138636755 @default.
• W2794897677 cites W2139730244 @default.
• W2794897677 cites W2140980839 @default.
• W2794897677 cites W2142760959 @default.
• W2794897677 cites W2144180913 @default.
• W2794897677 cites W2144660856 @default.
• W2794897677 cites W2144764793 @default.
• W2794897677 cites W2145835533 @default.
• W2794897677 cites W2148367564 @default.
• W2794897677 cites W2153942353 @default.
• W2794897677 cites W2157297793 @default.
• W2794897677 cites W2162643935 @default.
• W2794897677 cites W2170030318 @default.
• W2794897677 cites W2241884326 @default.
• W2794897677 cites W2255913386 @default.
• W2794897677 cites W2503271931 @default.
• W2794897677 doi "https://doi.org/10.1186/s12885-018-4150-y" @default.
• W2794897677 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5833040" @default.
• W2794897677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29499653" @default.
• W2794897677 hasPublicationYear "2018" @default.
• W2794897677 type Work @default.
• W2794897677 sameAs 2794897677 @default.
• W2794897677 citedByCount "8" @default.
• W2794897677 countsByYear W27948976772019 @default.
• W2794897677 countsByYear W27948976772020 @default.
• W2794897677 countsByYear W27948976772021 @default.
• W2794897677 countsByYear W27948976772022 @default.
• W2794897677 countsByYear W27948976772023 @default.
• W2794897677 crossrefType "journal-article" @default.
• W2794897677 hasAuthorship W2794897677A5003648443 @default.
• W2794897677 hasAuthorship W2794897677A5004024254 @default.
• W2794897677 hasAuthorship W2794897677A5004383942 @default.
• W2794897677 hasAuthorship W2794897677A5021722390 @default.
• W2794897677 hasAuthorship W2794897677A5022026164 @default.
• W2794897677 hasAuthorship W2794897677A5030688973 @default.
• W2794897677 hasAuthorship W2794897677A5036440015 @default.
• W2794897677 hasAuthorship W2794897677A5041846056 @default.
• W2794897677 hasAuthorship W2794897677A5047998541 @default.
• W2794897677 hasAuthorship W2794897677A5052453881 @default.
• W2794897677 hasAuthorship W2794897677A5053859585 @default.
• W2794897677 hasAuthorship W2794897677A5054884728 @default.
• W2794897677 hasAuthorship W2794897677A5057044706 @default.
• W2794897677 hasAuthorship W2794897677A5065387771 @default.
• W2794897677 hasAuthorship W2794897677A5066841617 @default.
• W2794897677 hasAuthorship W2794897677A5073524299 @default.
• W2794897677 hasAuthorship W2794897677A5077430155 @default.
• W2794897677 hasAuthorship W2794897677A5084744867 @default.
• W2794897677 hasAuthorship W2794897677A5087535894 @default.
• W2794897677 hasAuthorship W2794897677A5091073688 @default.
• W2794897677 hasBestOaLocation W27948976771 @default.
• W2794897677 hasConcept C126322002 @default.
• W2794897677 hasConcept C141071460 @default.
• W2794897677 hasConcept C143998085 @default.
• W2794897677 hasConcept C197934379 @default.

• next